Address
1 North Waukegan Road
North Chicago, IL 60064-6400
United States of America (the)
Phone
847 932 7900
Website
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
55000
First IPO Date
January 02, 2013
| Name | Title | Pay | Year Born |
| Robert A. Michael | Chief Executive Officer & Chairman of the Board | 7.42M | 1970 |
| Roopal Thakkar | Executive Vice President of Research and Development & Chief Scientific Officer | 3.56M | 1972 |
| Demetris D. Crum | Executive Vice President & Chief Human Resources Officer | 3.84M | 1981 |
| Scott T. Reents | Executive Vice President & Chief Financial Officer | 3.95M | 1968 |
| Azita Saleki-Gerhardt | Executive Vice President & Chief Operating Officer | 4.07M | 1963 |
| Jeffrey Ryan Stewart | Executive Vice President & Chief Commercial Officer | 5M | 1969 |
| Nicholas J. Donoghoe | Executive Vice President and Chief Business & Strategy Officer | 0 | 1981 |
| Elizabeth Shea | Senior Vice President of Investor Relations | 0 | N/A |
| Perry C. Siatis | Executive Vice President, General Counsel & Secretary | 0 | 1975 |
| Wulff-Erik von Borcke | Senior Vice President & President of Oncology | 0 | N/A |
| Linda Ray | Senior VP & Chief Information Officer | 0 | N/A |
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.